Ubs Group Ag Regencell Bioscience Holdings LTD Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Regencell Bioscience Holdings LTD stock. As of the latest transaction made, Ubs Group Ag holds 380 shares of RGC stock, worth $4,788. This represents 0.0% of its overall portfolio holdings.

Number of Shares

380

Previous 37,527 98.99%

Holding current value

$4,788

Previous $639,000 99.22%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$10.36 - $22.99 $384,842 - $854,009	-37,147 Reduced 98.99%	380 $5,000
Q2 2025 Aug 14, 2025	BUY	$15.66 - $877.0 $587,672 - $32.9 Million	37,527 New	37,527 $639,000
Q4 2024 Feb 14, 2025	BUY	$4.35 - $8.12 $49,337 - $92,097	11,342 Added 63.45%	29,218 $144,000
Q3 2024 Nov 14, 2024	BUY	$3.2 - $14.96 $56,204 - $262,757	17,564 Added 5629.49%	17,876 $99,000
Q2 2024 Aug 13, 2024	SELL	$3.36 - $6.49 $3,655 - $7,061	-1,088 Reduced 77.71%	312 $1,000

Q1 2024 May 13, 2024	SELL	$3.45 - $10.5 $50,552 - $153,856	-14,653 Reduced 91.28%	1,400 $6,000
Q4 2023 Feb 09, 2024	BUY	$9.22 - $17.66 $148,008 - $283,495	16,053 New	16,053 $168,000
Q1 2023 May 12, 2023	SELL	$25.23 - $30.19 $16,853 - $20,166	-668 Reduced 99.85%	1 $0
Q4 2022 Feb 08, 2023	BUY	$25.52 - $31.8 $3,087 - $3,847	121 Added 22.08%	669 $18,000
Q3 2022 Nov 10, 2022	SELL	$26.94 - $40.8 $4,714 - $7,139	-175 Reduced 24.2%	548 $17,000
Q2 2022 Aug 10, 2022	BUY	$20.67 - $45.78 $9,900 - $21,928	479 Added 196.31%	723 $25,000
Q1 2022 May 16, 2022	BUY	$21.4 - $40.0 $1,112 - $2,080	52 Added 27.08%	244 $5,000
Q4 2021 Feb 14, 2022	BUY	$13.43 - $32.87 $2,578 - $6,311	192 New	192 $6,000

Others Institutions Holding RGC

# of Institutions

Shares Held

625K

Call Options Held

73.8K

Put Options Held

105K

View Full List

About Regencell Bioscience Holdings Ltd

Ticker RGC
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,012,900
Market Cap $164M
Description
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated...

More about RGC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account